Assertio Therapeutics, Inc
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $57.9M | $128.4M | $380.7M | $455.9M | $342.7M | $390.4M |
| Operating income | $3.1M | $51.3M | −$6.7M | −$4.3M | −$50.4M | $236.8M |
| Net income | −$14.3M | $33.8M | −$26.7M | −$20.9M | −$75.7M | $131.8M |
| Total assets | $527.2M | $932.9M | $1.04B | $1.23B | $1.36B | $711.1M |
| Total liabilities | $469.2M | $712.5M | $869.1M | — | — | — |
| Equity | $58.0M | $220.3M | $169.5M | $250.8M | $315.1M | $364.4M |
| EPS (diluted) | $-0.22 | $0.48 | $-0.43 | $-0.34 | $-0.20 | $2.05 |
| Shares out. | 64.3M | 63.5M | 62.1M | 60.9M | 59.6M | 56.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- 5.3%
- Net margin
- −24.7%
- Return on equity
- −24.7%
- Return on assets
- −2.7%
- Return on capital (ROCE)
- 0.9%
- Liabilities / assets
- 89.0%
- Debt / equity
- 8.10×
- Book value / share
- $0.90
- Revenue growth (YoY)
- −54.9%
- Net income growth (YoY)
- −142.3%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -3.31distress
- Accruals / assets
- −19.9%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Delisting / listing-standard notice · Modified shareholder rights · Director / officer change · Amended charter or bylaws · Shareholder voteMay 22, 2020
- Results of operations · Other material eventMay 11, 2020
- Delisting / listing-standard noticeApr 24, 2020
- Other material eventApr 21, 2020
- Regulation FD disclosureApr 8, 2020
- Entered a material agreement · Director / officer change · Regulation FD disclosureMar 17, 2020
- Regulation FD disclosureMar 11, 2020
- Results of operationsMar 9, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.